한국간담췌외과학회지 (Annals of Hepato-Biliary-Pancreatic Surgery)

  • 제27권4호
  • /
  • Pages.415-422
  • /
  • 2023
  • /
  • 2508-5778(pISSN)
  • /
  • 2508-5859(eISSN)
한국간담췌외과학회 (The Korean Association of Hepato-Biliary-Pancreatic Surgery)
권호 표지
DOI QR코드

DOI QR Code

Exocrine pancreatic cancer as a second primary malignancy: A population-based study

  • Mee Joo Kang (Center for Liver and Pancreatobiliary Cancer, National Cancer Center) ;
  • Jiwon Lim (Division of Cancer Registration and Surveillance, National Cancer Center) ;
  • Sung-Sik Han (Center for Liver and Pancreatobiliary Cancer, National Cancer Center) ;
  • Hyeong Min Park (Center for Liver and Pancreatobiliary Cancer, National Cancer Center) ;
  • Sung Chun Cho (Center for Liver and Pancreatobiliary Cancer, National Cancer Center) ;
  • Sang-Jae Park (Center for Liver and Pancreatobiliary Cancer, National Cancer Center) ;
  • Sun-Whe Kim (Center for Liver and Pancreatobiliary Cancer, National Cancer Center) ;
  • Young-Joo Won (Division of Cancer Registration and Surveillance, National Cancer Center)
  • 투고 : 2023.04.11
  • 심사 : 2023.06.06
  • 발행 : 2023.11.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Backgrounds/Aims: Although cancer survivors are at higher risk of developing second primary malignancies, cancer surveillance strategies for them have not yet been established. This study aimed to identify first primary cancers that had high risks of developing second primary exocrine pancreatic cancer (EPC). Methods: Data on individuals diagnosed with primary cancers between 1993 and 2017 were obtained from the Korea Central Cancer Registry. The standardized incidence ratios (SIRs) of second primary EPCs were analyzed according to the primary tumor sites and follow-up periods. Results: Among the 3,205,840 eligible individuals, 4,836 (0.15%) had second primary EPCs, which accounted for 5.8% of the total EPC patients in Korea. Between 1 and 5 years after the diagnosis of first primary cancers, SIRs of second primary EPCs were increased in patients whose first primary cancers were in the bile duct (males 2.99; females 5.03) in both sexes, and in the small intestine (3.43), gallbladder (3.21), and breast (1.26) in females. Among those who survived 5 or more years after the diagnosis of first primary cancers, SIRs of second primary EPCs were elevated in patients whose first primary cancers were in the bile duct (males 2.61; females 2.33), gallbladder (males 2.29; females 2.22), and kidney (males 1.39; females 1.73) in both sexes, and ovary (1.66) and breast (1.38) in females. Conclusions: Survivors of first primary bile duct, gallbladder, kidney, ovary, and female breast cancer should be closely monitored for the occurrence of second primary EPCs, even after 5 years of follow-up.

키워드

과제정보

This work was supported by a research grant from the National Cancer Center, Republic of Korea (Grant numbers 1910132 and 2010040), Regional Innovation Strategy (RIS) through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (MOE) (2022RIS-005).

참고문헌

  1. Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin 2022;72:409-436. 
  2. Korea Central Cancer Registry, National Cancer Center. Annual report of cancer statistics in Korea in 2019. Goyang: Ministry of Health and Welfare; 2021 Dec. Report No.: 11-1352000-000145-10. 
  3. Wood ME, Vogel V, Ng A, Foxhall L, Goodwin P, Travis LB. Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol 2012;30:3734-3745. 
  4. Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, et al. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. Bethesda, MD: National Cancer Institute; 2006. NIH Publ. No. 05-5302. 
  5. Murphy CC, Gerber DE, Pruitt SL. Prevalence of prior cancer among persons newly diagnosed with cancer: an initial report from the surveillance, epidemiology, and end results program. JAMA Oncol 2018;4:832-836. 
  6. Donin N, Filson C, Drakaki A, Tan HJ, Castillo A, Kwan L, et al. Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer 2016;122:3075-3086. 
  7. Ahn HS, Kang TU, Swan H, Kang MJ, Kim N, Kim HJ, et al. Incidence and mortality rates of second pancreatic cancer among survivors of digestive cancers: a nationwide population-based study. Pancreas 2019;48:412-419. 
  8. Rahimi E, Batra S, Thosani N, Singh H, Guha S. Increased incidence of second primary pancreatic cancer in patients with prior colorectal cancer: a population-based US study. Dig Dis Sci 2016;61:1652-1660. 
  9. Amin S, McBride RB, Kline JK, Mitchel EB, Lucas AL, Neugut AI, et al. Incidence of subsequent pancreatic adenocarcinoma in patients with a history of nonpancreatic primary cancers. Cancer 2012;118:1244-1251. 
  10. Sung H, Hyun N, Leach CR, Yabroff KR, Jemal A. Association of first primary cancer with risk of subsequent primary cancer among survivors of adult-onset cancers in the United States. JAMA 2020;324:2521-2535. 
  11. Chung JW, Chung MJ, Bang S, Park SW, Song SY, Chung JB, et al. Assessment of the risk of colorectal cancer survivors developing a second primary pancreatic cancer. Gut Liver 2017;11:728-732. 
  12. Jo JH, Cho IR, Jung JH, Lee HS, Chung MJ, Bang S, et al. Clinical characteristics of second primary pancreatic cancer. PLoS One 2017;12:e0179784. 
  13. Niksic M, Matz M, Valkov M, Marcos-Gragera R, Stiller C, Rosso S, et al. World-wide trends in net survival from pancreatic cancer by morphological sub-type: an analysis of 1,258,329 adults diagnosed in 58 countries during 2000-2014 (CONCORD-3). Cancer Epidemiol 2022;80:102196. 
  14. Kang MJ, Won YJ, Lee JJ, Jung KW, Kim HJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2019. Cancer Res Treat 2022;54:330-344. 
  15. Working Group Report. International rules for multiple primary cancers (ICD-0 third edition). Eur J Cancer Prev 2005;14:307-308. 
  16. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International classification of diseases for oncology, 3rd ed [Internet]. 2000 [cited 2022 Oct 27]. Available from: https://apps.who.int/iris/handle/10665/42344. 
  17. Fritz A. SEER program code manual. third edition. National Cancer Institute, 1998. 
  18. Man D, Wu J, Shen Z, Zhu X. Prognosis of patients with neuroendocrine tumor: a SEER database analysis. Cancer Manag Res 2018;10:5629-5638. 
  19. Kang MJ, Lim J, Han SS, Park HM, Park SJ, Won YJ, et al. First course of treatment and prognosis of exocrine pancreatic cancer in Korea from 2006 to 2017. Cancer Res Treat 2022;54:208-217. 
  20. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K; International Agency for Research on Cancer Handbook Working Group. Body fatness and cancer-viewpoint of the IARC Working Group. N Engl J Med 2016;375:794-798. 
  21. Park CY, Lim JY, Park HY. Age at natural menopause in Koreans: secular trends and influences thereon. Menopause 2018;25:423-429. 
  22. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Solid tumor rules: Kidney, 2020. 
  23. Begg CB. Methodological and statistical considerations in the study of multiple primary cancers. In: Neugut AI, Meadows AT, Robinson E, eds. Multiple Primary Cancers. Lippincott Williams & Wilkins, 1999:13-26. 
  24. Shen M, Boffetta P, Olsen JH, Andersen A, Hemminki K, Pukkala E, et al. A pooled analysis of second primary pancreatic cancer. Am J Epidemiol 2006;163:502-511. 
  25. Min SK, Choi SW, Lim J, Park JY, Jung KW, Won YJ. Second primary cancers in patients with oral cavity cancer included in the Korea Central Cancer Registry. Oral Oncol 2019;95:16-28. 
  26. Lin Y, Tamakoshi A, Kawamura T, Inaba Y, Kikuchi S, Motohashi Y, et al. Risk of pancreatic cancer in relation to alcohol drinking, coffee consumption and medical history: findings from the Japan collaborative cohort study for evaluation of cancer risk. Int J Cancer 2002;99:742-746. 
  27. Kamath GR, Kim MK, Taioli E. Risk of primary neuroendocrine pancreatic tumor after a first primary cancer: a US population-based study. Pancreas 2019;48:161-168. 
  28. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Survivorship, version 1. 2022 [cited 2022 Dec 2]. Available from: https://www.nccn.org/guidelines. 
  29. Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol 2016;34:611-635. 
  30. Yun EH, Hong S, Her EY, Park B, Suh M, Choi KS, et al. Trends in Participation Rates of the National Cancer Screening Program among Cancer Survivors in Korea. Cancers (Basel) 2020;13:81. 
  31. Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB, et al. Cancer survivorship-genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 2006;98:15-25. 
  32. Neugut AI, Ahsan H, Robinson E. Pancreas cancer as a second primary malignancy. A population-based study. Cancer 1995;76:589-592. 
  33. Park S, Jee SH, Shin HR, Park EH, Shin A, Jung KW, et al. Attributable fraction of tobacco smoking on cancer using population-based nationwide cancer incidence and mortality data in Korea. BMC Cancer 2014;14:406. 
  34. Gandini S, Botteri E, Iodice S, Boniol M, Lowenfels AB, Maisonneuve P, et al. Tobacco smoking and cancer: a meta-analysis. Int J Cancer 2008;122:155-164. 
  35. Park S, Bae J, Nam BH, Yoo KY. Aetiology of cancer in Asia. Asian Pac J Cancer Prev 2008;9:371-380. 
  36. Zhong L, Liu J, Liu S, Tan G. Correlation between pancreatic cancer and metabolic syndrome: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2023;14:1116582. 
  37. Xia B, He Q, Pan Y, Gao F, Liu A, Tang Y, et al. Metabolic syndrome and risk of pancreatic cancer: a population-based prospective cohort study. Int J Cancer 2020;147:3384-3393. 
  38. Kim BW, Oh CM, Choi HY, Park JW, Cho H, Ki M. Incidence and overall survival of biliary tract cancers in South Korea from 2006 to 2015: using the National Health Information Database. Gut Liver 2019;13:104-113. 
  39. Hwang YJ, Park SM, Ahn S, Lee JC, Park YS, Kim N. Accuracy of an administrative database for pancreatic cancer by international classification of disease 10th codes: a retrospective large-cohort study. World J Gastroenterol 2019;25:5619-5629.